bamlanivimab/etesevimab for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results	clinical improvement E	hospitalization or death E
COVID 19 outpatients meta-analysis
BLAZE-1 phase 3 (combo) NCT04427501		RCT	bamlanivimab/etesevimab	placebo	COVID 19 outpatients	some concern	518/517	suggested
BLAZE-1 phase 2 (combination with etesevimab) NCT04427501		RCT	bamlanivimab/etesevimab	placebo	COVID 19 outpatients	some concern	112/156	inconclusive
2 studies excluded by filtering options (2 RCT / 0 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 outpatients meta-analysis